• efficacy
  • In a one-day public conference held in July 2012, members from AABB and others in the transfusion medicine community discussed the risks posed by bacterial contamination of platelets and the potential benefits, costs, and efficacy of secondary bacterial screening tests. (transfusionnews.com)
  • count
  • A prolonged bleeding time in a patient with a normal platelet count is indicative of a qualitative platelet abnormality, von Willebrand disease (see Chap. 135), or afibrinogenemia (see Chap. 124). (wordpress.com)
  • The test is typically ordered along with or following a platelet count and may be followed by additional tests such as functional assays to confirm a finding. (labtestsonline.org)
  • The presence of HIT antibodies in someone who has been treated with heparin for 5 to 10 days, has a platelet count that has decreased by 50% or more, and has new blood clots means that it is likely the person has HIT II. (labtestsonline.org)
  • receptor
  • Background -The present study describes the effects of tirofiban, a nonpeptide platelet glycoprotein (GP) IIb/IIIa receptor blocker, on the characteristics of culprit lesions in patients with unstable angina (UA) or non-Q-wave myocardial infarction (NQWMI). (ahajournals.org)
  • size
  • Platelet size (determined from the blood film and/or the mean platelet volume) helps to separate the inherited quantitative platelet syndromes from the acquired thrombocytopenias and the inherited combined quantitative and qualitative thrombocytopenias (see Chap. 117). (wordpress.com)
  • patients
  • Since 15 patients with PVT (2 with cirrhotic PVT and 13 with non-cirrhotic PVT) and 10 patients with Budd-Chiari syndrome were treated with warfarin at the time of the blood sampling, an equal number of patients matched for age, gender and prothrombin time-international normalized ratio with atrial fibrillation and no hepatic diseases were used as controls. (diva-portal.org)
  • study
  • A study published in the journal Blood suggests that low to moderate levels of human leukocyte antigen (HLA) antibodies are not predictive of platelet transfusion failure. (transfusionnews.com)
  • 12 13 14 15 The PRISM-PLUS study investigated tirofiban, a nonpeptide platelet GP IIb/IIIa antagonist, as part of the comprehensive management of UA or NQWMI. (ahajournals.org)
  • standard
  • All three trials compared a standard trigger (10 x 109/L) versus a higher trigger (20 x 109/L or 30 x 109/L). None of the trials compared a low trigger versus a standard trigger or an alternative platelet trigger. (ox.ac.uk)